These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 22215356)

  • 1. Aztreonam lysine for inhalation: new formulation of an old antibiotic.
    Zeitler K; Salvas B; Stevens V; Brown J
    Am J Health Syst Pharm; 2012 Jan; 69(2):107-15. PubMed ID: 22215356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine.
    Elborn JS; Henig NR
    Expert Opin Pharmacother; 2010 Jun; 11(8):1373-85. PubMed ID: 20426707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhaled aztreonam.
    O'Sullivan BP; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2010 May; 9(5):357-8. PubMed ID: 20431562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aztreonam lysine: a novel inhalational antibiotic for cystic fibrosis.
    Parkins MD; Elborn JS
    Expert Rev Respir Med; 2010 Aug; 4(4):435-44. PubMed ID: 20658904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.
    McCoy KS; Quittner AL; Oermann CM; Gibson RL; Retsch-Bogart GZ; Montgomery AB
    Am J Respir Crit Care Med; 2008 Nov; 178(9):921-8. PubMed ID: 18658109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhaled aztreonam lysine for cystic fibrosis pulmonary disease-related outcomes.
    Pesaturo KA; Horton ER; Belliveau P
    Ann Pharmacother; 2012; 46(7-8):1076-85. PubMed ID: 22764322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aztreonam lysine for inhalation solution: in cystic fibrosis.
    Plosker GL
    Drugs; 2010 Oct; 70(14):1843-55. PubMed ID: 20836577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhaled aztreonam lysine: an evidence-based review.
    Hutchinson D; Barclay M; Prescott WA; Brown J
    Expert Opin Pharmacother; 2013 Oct; 14(15):2115-24. PubMed ID: 23992352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for the efficacy of aztreonam for inhalation solution in the management of Pseudomonas aeruginosa in patients with cystic fibrosis.
    Hansen C; Skov M
    Ther Adv Respir Dis; 2015 Feb; 9(1):16-21. PubMed ID: 25471692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study.
    Tiddens HA; De Boeck K; Clancy JP; Fayon M; H G M A; Bresnik M; Derchak A; Lewis SA; Oermann CM;
    J Cyst Fibros; 2015 Jan; 14(1):111-9. PubMed ID: 25091537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aerosolized antibiotics in cystic fibrosis: an update.
    Fiel SB
    Expert Rev Respir Med; 2014 Jun; 8(3):305-14. PubMed ID: 24838090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection.
    Retsch-Bogart GZ; Burns JL; Otto KL; Liou TG; McCoy K; Oermann C; Gibson RL;
    Pediatr Pulmonol; 2008 Jan; 43(1):47-58. PubMed ID: 18041081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis.
    Oermann CM; Retsch-Bogart GZ; Quittner AL; Gibson RL; McCoy KS; Montgomery AB; Cooper PJ
    Pediatr Pulmonol; 2010 Nov; 45(11):1121-34. PubMed ID: 20672296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI).
    Oermann CM; McCoy KS; Retsch-Bogart GZ; Gibson RL; McKevitt M; Montgomery AB
    J Antimicrob Chemother; 2011 Oct; 66(10):2398-404. PubMed ID: 21784781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of inhaled aztreonam on the cystic fibrosis lung microbiome.
    Heirali AA; Workentine ML; Acosta N; Poonja A; Storey DG; Somayaji R; Rabin HR; Whelan FJ; Surette MG; Parkins MD
    Microbiome; 2017 May; 5(1):51. PubMed ID: 28476135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Desensitization to inhaled aztreonam lysine in an allergic patient with cystic fibrosis using a novel approach.
    Guglani L; Abdulhamid I; Ditouras J; Montejo J
    Ann Pharmacother; 2012 Oct; 46(10):e25. PubMed ID: 23012384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis.
    Retsch-Bogart GZ; Quittner AL; Gibson RL; Oermann CM; McCoy KS; Montgomery AB; Cooper PJ
    Chest; 2009 May; 135(5):1223-1232. PubMed ID: 19420195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials.
    Máiz L; Girón RM; Olveira C; Quintana E; Lamas A; Pastor D; Cantón R; Mensa J
    Expert Opin Pharmacother; 2013 Jun; 14(9):1135-49. PubMed ID: 23586963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhaled aztreonam lysine versus inhaled tobramycin in cystic fibrosis. An economic evaluation.
    Schechter MS; Trueman D; Farquharson R; Higuchi K; Daines CL
    Ann Am Thorac Soc; 2015 Jul; 12(7):1030-8. PubMed ID: 26053185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of nebulised aztreonam lysine (AZLI) in aztreonam hypersensitive patients.
    Whitaker P; Etherington C; Williams K; Conway S; Peckham D
    J Cyst Fibros; 2012 Jul; 11(4):353. PubMed ID: 22341263
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.